Jamshidi, ElhamAsgary, AmirhosseinShafiekhani, PariaKhajeamiri, YasamanMohamed, KawtharEsmaily, HadiJamal Rahi, SahandMansouri, Nahal2022-04-252022-04-252022-04-252022-04-1410.1080/21645515.2022.2037384https://infoscience.epfl.ch/handle/20.500.14299/187382WOS:000782353400001It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccineModified Letter Turned Commas antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.Biotechnology & Applied MicrobiologyImmunologycovid-19vaccinessars-cov-2immunogenicityhumoral immunitycell-mediated immunityantibody persistencelong-term protectionlong-term immunityqualitydiseasetrialstext::journal::journal article::review article